enVVeno Medical Q3 2026 net loss narrows to $4.4 million

• enVVeno Medical’s third-quarter 2026 net loss narrowed year over year to $4.4 million.
• Operating expenses fell 8% year over year to $4.5 million.
• Quarter-end cash and investments totaled $18.5 million, expected to fund operations into the fourth quarter of 2027.
• The FDA-approved TAVVE pivotal study remains on track to enroll its first patient before year-end 2026.
• Quarterly cash burn totaled $3 million, with $4 million to $5 million expected in the first half of 2027 during continued TAVVE enrollment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enVVeno Medical Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202610300830ACCESSWRNAPR_____1244058) on October 30, 2026, and is solely responsible for the information contained therein.